title: Gender-specific effects of CGP 55845, GABAB receptor antagonist, on neuromuscular coordination, learning and memory formation in albino mouse following neonatal hypoxia-ischemia insult.
abstract: GABAB receptor antagonists are experimentally proved as spatial memory enhancers in mouse models but their role has not been described following hypoxic-ischemic insult. 10-day-old albino mice were subjected to Murine model of hypoxia and ischemia. Following brain damage, mice were fed on normal rodent diet till they were 13 weeks old. At this time point, mice were divided into two groups. Group 1 received saline and group 2 received intraperitoneally CGP 55845 (1 mg/ml solvent/Kg body weight) for 12 days. Behavioural observations were made during rota rod, open field and Morris water maze test along with brain infarct measurement in both CGP 55845 treated and untreated groups. It was observed that application of GABAB receptor antagonist improved the over all motor function in male and female albino mice but effects were more pronounced in males. In open field, CGP 55845-treated female mice showed poor performance. CGP 55845 had no significant effect on learning and memory formation during Morris water maze test and also on brain infract size in both genders following hypoxia ischemia encephalopathy. Effects of CGP 55845 can be further explored in a dose and duration dependent manner to improve the learning and memory in albino mice following neonatal brain damage.
authors.affiliation: Zoology Division, Department of Zoology, Institute of Pure and Applied Biology, Bahauddin Zakariya University, Multan, 60800, Pakistan.
authors.forename: Quratul Ane
authors.initials: QA
authors.lastname: Gillani
authors.forename: Atif
authors.initials: A
authors.lastname: Akbar
authors.forename: Muhammad
authors.initials: M
authors.lastname: Ali
authors.forename: Furhan
authors.initials: F
authors.lastname: Iqbal
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D001522:Behavior, Animal / Q000187:drug effects*; D001921:Brain / Q000187:drug effects* / Q000503:physiopathology; D004195:Disease Models, Animal; D005260:Female; D058788:GABA-B Receptor Antagonists / Q000494:pharmacology*; D020925:Hypoxia-Ischemia, Brain / Q000188:drug therapy; D007511:Ischemia / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D018782:Maze Learning / Q000187:drug effects*; D008568:Memory / Q000187:drug effects*; D051379:Mice; D010721:Phosphinic Acids / Q000494:pharmacology*; D011412:Propanolamines / Q000494:pharmacology*; D012727:Sex Characteristics
chemical_list: D058788:GABA-B Receptor Antagonists; D010721:Phosphinic Acids; D011412:Propanolamines; C085075:CGP 55845A
references.citation: J Leukoc Biol. 2005 Aug;78(2):393-400
references.pmid: 15908457
references.citation: Neuropharmacology. 2000 Jan 28;39(3):449-62
references.pmid: 10698011
references.citation: Neuron. 1988 Sep;1(7):585-91
references.pmid: 2856099
references.citation: Biomed Res Int. 2014;2014:295215
references.pmid: 24804211
references.citation: Brain Res. 2001 Nov 9;918(1-2):153-65
references.pmid: 11684053
references.citation: J Neurosci. 2012 Jul 4;32(27):9217-27
references.pmid: 22764230
references.citation: J Neurosci. 1999 Jun 1;19(11):4609-15
references.pmid: 10341258
references.citation: J Neurophysiol. 1993 Jul;70(1):448-52
references.pmid: 8395587
references.citation: Mol Cell Biol. 1994 Jun;14(6):3981-92
references.pmid: 8196637
references.citation: Neurol Sci. 2015 May;36(5):765-70
references.pmid: 25511980
references.citation: Eur J Pharmacol. 1993 Mar 23;233(2-3):179-86
references.pmid: 8385620
references.citation: Early Hum Dev. 1991 Jul;26(1):61-7
references.pmid: 1914989
references.citation: Arch Dis Child. 2005 May;90(5):474-9
references.pmid: 15851428
references.citation: Eur J Pharmacol. 1997 Feb 5;320(1):9-13
references.pmid: 9049596
references.citation: Neuron. 1993 Feb;10 (2):165-75
references.pmid: 7679913
references.citation: Behav Brain Res. 2005 Feb 10;157(1):157-65
references.pmid: 15617782
references.citation: Stroke. 2004 Sep;35(9):2183-8
references.pmid: 15272130
references.citation: Physiol Rev. 2004 Jul;84(3):835-67
references.pmid: 15269338
references.citation: J Neurochem. 2006 Feb;96(4):1016-27
references.pmid: 16412092
references.citation: Pharmacol Rep. 2007 Nov-Dec;59(6):757-62
references.pmid: 18195467
references.citation: Hippocampus. 2004;14(1):135-40
references.pmid: 15058491
references.citation: Trends Pharmacol Sci. 2005 Jan;26(1):36-43
references.pmid: 15629203
references.citation: J Pharmacol Exp Ther. 2005 Jan;312(1):290-6
references.pmid: 15333677
references.citation: J Med Chem. 1995 Aug 18;38(17):3313-31
references.pmid: 7650685
references.citation: N Engl J Med. 2005 Jan 6;352(1):9-19
references.pmid: 15635108
references.citation: J Neurophysiol. 1994 Nov;72(5):2317-27
references.pmid: 7884461
references.citation: ScientificWorldJournal. 2014 Jan 19;2014:983651
references.pmid: 24574938
references.citation: Neuroscience. 1999;93(4):1241-9
references.pmid: 10501448
references.citation: Brain Res. 1988 Aug 30;459(1):200-3
references.pmid: 3048538
references.citation: Neuroscience. 1996 Sep;74(2):331-9
references.pmid: 8865186
references.citation: Neurol Sci. 2015 Jan;36(1):73-8
references.pmid: 25082078